International prognostic index-based outcomes for diffuse large B-cell lymphomas

✍ Scribed by Richard B. Wilder; Maria A. Rodriguez; L. Jeffrey Medeiros; Susan L. Tucker; Chul S. Ha; Jorge E. Romaguera; Barbara Pro; Mark A. Hess; Fernando Cabanillas; James D. Cox

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 106 KB
• Volume: 94
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.10583

✦ Synopsis

Abstract

BACKGROUND

We present the results of doxorubicin‐based chemotherapy with or without involved‐field radiotherapy for patients with diffuse large B‐cell lymphoma (DLBCL) according to the international prognostic index (IPI).

METHODS

From September 1988 through December 1996, 294 patients with Stage I–IV Working Formulation large B‐cell or T‐cell lymphomas were treated prospectively on two protocols at our center. Diagnoses were reclassified subsequently according to the new World Health Organization classification. Two‐hundred and twenty‐four patients had DLBCL, including 24 patients with primary mediastinal large B‐cell lymphoma. Treatment consisted of a median of six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy with or without involved‐field radiotherapy (median dose, 39.6 Gy).

RESULTS/CONCLUSIONS.

The median length of follow‐up among surviving patients was 5.0 years. Patient subgroups differed from each other in terms of progression‐free (P = 0.003), cause‐specific (P = 0.003), and overall (P = 0.001) survival rates when analyzed by IPI. Five‐year progression‐free, cause‐specific, and overall survival rates for 212 patients with an IPI of 0–2 were 73%, 84%, and 82%, respectively, versus only 37%, 33%, and 32% for 12 patients with an IPI of 3–4. To improve our results, we are conducting clinical trials with young DLBCL patients and with patients who are older than 60 years. The young DLBCL patients, who have more than two adverse prognostic features, are receiving high‐dose chemotherapy and autologous stem cell rescue. The patients who are older than 60 years, regardless of IPI, are receiving rituximab immunotherapy and liposomal CHOP chemotherapy with or without involved‐field radiotherapy. Cancer 2002;94:3083–8. © 2002 American Cancer Society.

DOI 10.1002/cncr.10583